Saturday 7 November 2026 Export BNTC’s income statement to Excel — free account

Benitec Biopharma Limited

BNTC Healthcare Biotechnology

Benitec Biopharma Limited’s revenue for fiscal 2023 (year ended June 2023) was $75,000.00, up 2.74% from fiscal 2022.

EPS: −11.3%
Free cash flow: +38.9%
Total debt: −46.3%

Quarter to June 2026, against a year earlier

9.50 0.86 +9.95%

Follow BNTC

Alert me

Market cap: $301.5M
P/E: 0.0×
Fwd P/E: −1.8×
Dividend yield: —
F-score: 3/9
Altman Z: −66.02
Beneish M: 11.02
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 2.44

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	2	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 26.95%

Capital & Financial Ratios $m

Size

Market Cap 301.45

Revenue ttm 0.08

Net income ttm (45.55)

Free cash flow ttm (16.62)

Net debt Q (179.82)

Valuation

P/E 0.00

Forward P/E (1.79)

Price / sales 5,897.35

Forward P/S Powerpack

Price / FCF 0.00

Price / book 2.50

Financial health

Current ratio Q 34.00

Debt / equity Q 0.00

Interest coverage Q (1,036.75)

Growth

Revenue growth Q −85.42%

Operating income growth Q −46.74%

EPS, this year −26.28%

EPS, next year A −20.00%

Revenue, next year A +101.33%

EPS, past 5 yrs —

EPS, next 5 yrs A −11.27%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 77.89%

10-year low 10-year high

P/B against its own 10 years 71.89%

10-year low 10-year high

EV/Sales against its own 10 years 56.12%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —
Growth, 2018–20: −100.0%/yr

0.77 ’18
0.00 ’19 −100
0.00 ’20

paid change on the year, %

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	2	51	98	180
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	1	1	1	2
	4	52	99	182

	2023	2024	2025	2026
Payables	3	4	1	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	5	2	5

Compound Annual Growth %

	10y	5y	3y
Sales	(32.19%)	(54.02%)	(9.74%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	29.14%	54.65%	856.94%

Earnings Trends EPS, adjusted, against the consensus

Q4 FY26 Estimate −0.26 Actual −0.26

−0.37 −0.33 −0.29 −0.24 −0.20

Q1 FY26 Beat +0.13

Q2 FY26 Miss −0.03

Q3 FY26 Beat +0.03

Q4 FY26 Met 0.00

Q1 FY27 — Nov 13

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q1 FY26	−0.35	−0.22	Beat by 0.13
Q2 FY26	−0.23	−0.26	Miss by 0.03
Q3 FY26	−0.27	−0.24	Beat by 0.03
Q4 FY26	−0.26	−0.26	Met by 0.00
Q1 FY27	−0.30	—	Reports 13 November 2026

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(0.22)	(0.26)	(0.24)	(0.26)	(0.98)
’25	(0.18)	(0.26)	(0.38)	(0.23)	(1.05)
’24	(2.76)	(2.64)	(0.23)	(0.18)	(1.18)
’23	(7.99)	(3.40)	(2.72)	(0.13)	(14.12)
’22	(2.10k)	(10.03)	(6.80)	(10.54)	(37.92)
’21	(41.67)	(12.86)	(13.95)	(5.10)	(54.93)

Fiscal quarters ending in the months shown.

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’23	—	0	0	0	0
’22	—	0	0	0	0
’21	0	0	0	0	0
’20	0	0	0	0	0
’19	—	—	—	—	12
’18	1	—	—	—	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(3)	(4)	(4)	(5)	(17)
’25	(5)	(8)	(3)	(8)	(24)
’24	(5)	(5)	(6)	(3)	(19)
’23	(4)	(6)	(4)	(4)	(18)
’22	(4)	(3)	(3)	(5)	(16)
’21	(2)	(3)	(2)	(5)	(13)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(3)	(4)	(4)	(5)	(17)
’25	(5)	(8)	(3)	(8)	(24)
’24	(5)	(5)	(6)	(3)	(20)
’23	—	—	(4)	(4)	(18)
’23	(4)	(6)	—	—	(18)
’22	—	—	(3)	(5)	(16)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	Trend	10 yrs	2027e	2028e	2029e	Next 3/yr
												Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	8	4	12	0	0	0	0	—	—	—		(54.4%)	—	—	—	—
	Gross margin, %	52.34	(17.80)	96.43	281.37	(108.47)	87.67	100.00	0.00	—	—		(52.3) pt	Powerpack Benitec Biopharma Limited’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(4)	(9)	3	(8)	(14)	(18)	(20)	(22)	(38)	(46)		+30.0%
	EBT margin, %	(51.29)	(247.29)	21.39	(8,111.76)	(23,528.81)	(24,942.47)	(26,082.67)	0.00	0.00	0.00		+51.3 pt
	Net income	0	(9)	3	(8)	(14)	(18)	(20)	(22)	(38)	(46)		n/m
Per share, $
Per share, $	Revenue	243.11	88.36	242.04	340.00	0.23	0.15	0.05	0.00	0.00	0.00		n/m
	Earnings	(124.99)	(219.38)	51.77	(27,591.04)	(54.93)	(37.92)	(14.12)	(1.18)	(1.05)	(0.98)		(41.7%)
	Cash flow	(181.99)	(183.86)	95.04	(25,116.67)	(50.82)	(33.07)	(13.00)	(1.06)	(0.65)	(0.35)		(50.0%)
	Capex	(3.75)	(1.52)	(7.94)	(313.33)	(0.88)	(0.03)	0.00	(0.01)	0.00	0.00		(56.0%)
	Free cash flow	(185.74)	(185.38)	87.10	(25,430.00)	(51.69)	(33.10)	(13.00)	(1.07)	(0.65)	(0.36)		(50.1%)
	Book value	471.32	351.87	329.25	34,126.67	79.25	6.00	0.15	2.57	2.69	3.80		(41.5%)
	Shares, m	0	0	0	0	0	0	1	18	36	47		+122.8%
Valuation, ×
Valuation, ×	P/E	23.13	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—		3.3
	P/S	0.00	0.00	0.00	0.40	309.21	126.39	74.84	—	—	—		73.0
	P/B	0.91	1.22	0.44	0.00	0.91	3.29	27.79	—	—	—		4.9
	EV/Sales	0.00	0.00	0.00	(93.60)	(25.20)	79.50	45.43	—	—	—		0.9
	EV/FCF	(0.18)	(0.64)	0.50	1.25	0.11	(0.37)	(0.19)	—	—	—		0.1
Cash, $m
Cash, $m	Operating cash flow	(6)	(8)	5	(8)	(13)	(16)	(18)	(19)	(24)	(17)		+11.4%
	Capex	0	0	0	0	0	0	0	0	0	0		(2.3%)
	Free cash flow	(6)	(8)	4	(8)	(13)	(16)	(18)	(20)	(24)	(17)		+11.2%
Balance, $m
Balance, $m	Working capital	16	14	16	10	19	2	0	47	97	176		+30.7%
	Net debt	(13)	(12)	(16)	(10)	(20)	(4)	(2)	(51)	(97)	(180)		+33.8%
	Shareholders’ equity	16	15	17	10	20	3	0	47	97	177		+30.4%
Returns, %
Returns, %	ROA	(27.17)	(53.67)	14.58	(53.69)	(84.22)	(133.14)	(374.86)	(78.94)	(49.96)	(32.28)		(5.1) pt
	ROIC	(81.96)	(271.58)	184.29	(796.25)	(3,759.96)	0.00	0.00	0.00	0.00	0.00		+82.0 pt
	ROE	(28.66)	(58.70)	16.76	(61.67)	(91.79)	(159.08)	(1,268.61)	(94.29)	(52.46)	(33.21)		(4.5) pt
People
People	Employees	18	15	21	14	14	18	18	16	19	24		+3.2%
	Revenue/emp, $m	0.46	0.24	0.58	0.01	0.00	0.00	0.00	0.00	0.00	0.00		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Jun 2023 · latest quarter Jun 2023 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EIKN Eikon Therapeutics, Inc.	$316.3M	— (loss-making)	—	—	n/m	+15.18% (above 0%: growing)	—	0.00%	Compare
ALEC Alector, Inc.	$309.9M	6.6×	— (loss-making)	+4,895.89% (above 0%: growing)	n/m	+25.73% (above 0%: growing)	100.00%	76.04%	Compare
XFOR X4 Pharmaceuticals, Inc.	$304.4M	— (loss-making)	— (loss-making)	+63.12% (above 0%: growing)	n/m	+27.45% (above 0%: growing)	82.18%	(694.37%)	Compare
BNTC Benitec Biopharma Limited	$301.5M	— (loss-making)	— (loss-making)	−85.42% (below 0%: shrinking)	n/m	+38.90% (above 0%: growing)	0.00%	0.00%
GALT Galectin Therapeutics Inc.	$301.0M	— (loss-making)	—	—	n/m	+63.06% (above 0%: growing)	0.00%	0.00%	Compare
ENTA Enanta Pharmaceuticals, Inc.	$293.6M	— (loss-making)	— (loss-making)	−21.60% (below 0%: shrinking)	n/m	−157.51% (below 0%: shrinking)	100.00%	(120.04%)	Compare
SCTX Scribe Therapeutics Inc.	$293.1M	—	—	—	n/m	—	100.00%	(489.83%)	Compare
AGEN Agenus Inc.	$290.8M	10.7×	27.7×	+4.14% (above 0%: growing)	−99.00% (below 0%: shrinking)	−37.06% (below 0%: shrinking)	100.00%	36.23%	Compare
KYTX Kyverna Therapeutics, Inc.	$285.1M	— (loss-making)	— (loss-making)	—	n/m	−27.06% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$297.3M	—	—	+33.63%	—	+15.18%	100.00%	0.00%

All 621 Biotechnology stocks →

Benitec Biopharma Limited (BNTC) Latest News

28 Oct

Impact 4 · 8:00 AM · GlobeNewswire

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

5 Oct

Impact 3 · 8:00 AM · GlobeNewswire

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

25 Sep

Impact 3 · 8:35 AM · Zacks

After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)

14 May

Impact 3 · 8:00 AM · GlobeNewswire

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

28 Apr

Impact 4 · 7:00 AM · GlobeNewswire

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

10 Mar

Impact 3 · 7:00 AM · GlobeNewswire

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

9 Mar

Impact 4 · 7:00 AM · GlobeNewswire

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

23 Feb

Impact 3 · 7:00 AM · GlobeNewswire

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

14 Feb

Impact 3 · 8:27 AM · Simply Wall St.

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

12 Feb

Impact 3 · 8:30 AM · GlobeNewswire

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

11 Jan

Impact 4 · 8:00 AM · GlobeNewswire

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

24 Dec

Impact 4 · 9:55 AM · Zacks

Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

5 Dec

Impact 4 · 9:55 AM · ZacksZacksZacksZacksZacksZacksZacksZacks

Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know

3 Dec

Impact 3 · 9:35 AM · ZacksZacksZacksZacksZacksZacksZacksZacks

Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)

18 Nov

Impact 4 · 6:16 AM · Insider MonkeyInsider MonkeyInsider MonkeyMT NewswiresInsider Monkey

Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment

Impact 3 · 5:27 AM · Simply Wall St.

Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership

14 Nov

Impact 3 · 5:00 PM · GlobeNewswireMotley FoolGuruFocus.comMotley FoolGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

12 Nov

Impact 4 · 9:45 AM · 24/7 Wall St.

Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others

6 Nov

Impact 3 · 12:19 AM · GlobeNewswire

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

5 Nov

Impact 3 · 4:43 PM · GlobeNewswireMT NewswiresMT NewswiresMT NewswiresBioPharma DiveMT NewswiresMT NewswiresMT Newswires

Benitec Biopharma Inc. Announces Proposed Public Offering

3 Nov

Impact 4 · 7:10 AM · GlobeNewswire

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Impact 3 · 7:00 AM · GlobeNewswire

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

2 Nov

Impact 4 · 7:00 PM · GlobeNewswire

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

22 Sep

Impact 4 · 4:05 PM · GlobeNewswire

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

17 Aug

Impact 4 · 8:02 AM · Simply Wall St.

We're Interested To See How Benitec Biopharma (NASDAQ:BNTC) Uses Its Cash Hoard To Grow

9 Jul

Impact 4 · 8:00 AM

Benitec Biopharma Provides Operational Updates

5 Jun

Impact 4 · 9:55 AM · Zacks

Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

4 Jun

Impact 3 · 9:40 AM · Zacks

Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?

20 May

Impact 4 · 9:55 AM

Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet

19 May

Impact 4 · 9:40 AM · Zacks

Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to June

Benitec Biopharma Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Benitec Biopharma Limited (BNTC) Latest News

28 Oct

5 Oct

25 Sep

14 May

28 Apr

10 Mar

9 Mar

23 Feb

14 Feb

12 Feb

11 Jan

24 Dec

5 Dec

3 Dec

18 Nov

14 Nov

12 Nov

6 Nov

5 Nov

3 Nov

2 Nov

22 Sep

17 Aug

9 Jul

5 Jun

4 Jun

20 May

19 May

Stockrow Weekly